News | November 30, 2022
Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
The CRL did not identify any outstanding scientific issues with the product.
The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Construction is now underway with the facility scheduled to be operational by 2025
The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools
The WAVEsystem with the WAVEcontrol 4.0 embedded
Syngene's collaboration with Zoetis started in 2011
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
Subscribe To Our Newsletter & Stay Updated
